Readers’ editor blog: Comments, comments everywhere
6 Mar, 13 | by BMJ Group
Yesterday morning the BMJ’s press officer needed to locate a rapid response about Tamiflu from Peter Doshi, a postdoctoral fellow at Johns Hopkins University, Baltimore. Doshi’s response accuses the drug’s manufacturer Roche of “all talk and no action” following its promise to share full clinical study reports (CSRs) for 10 treatment trials.
Our Tamiflu open data campaign page was a logical starting point. It wasn’t there. Doshi had in fact responded to this news story, posted last week: Roche says it will not relinquish control over access to clinical trial data. more…
